Patient Stratification
"Digistain has shown statistically significant prognostic ability for ER-positive, HER2-negative primary operable breast cancer by stratifying patients into high and low risk. With currently over-burdened healthcare systems and the need to improve global cancer care inequalities, the ability to provide low-cost, rapid, and widely accessible prognostic testing suggests that Digistain may have the potential for significant clinical utility".
Professor Charles Coombes, FMedSciDirector of The Imperial CRUK Cancer Centre "Digistain has shown statistically significant prognostic ability for ER-positive, HER2-negative primary operable breast cancer by stratifying patients into high and low risk. With currently over-burdened healthcare systems and the need to improve global cancer care inequalities, the ability to provide low-cost, rapid, and widely accessible prognostic testing suggests that Digistain may have the potential for significant clinical utility".
Clinical experience
“When clinicopathological factors are augmented with objective assessment of grading, risk evaluation consistency complements existing genomic risk tools.”
Professor William Dooley, MD FACSProfessor of Surgical Oncology, Johns Hopkins University “When clinicopathological factors are augmented with objective assessment of grading, risk evaluation consistency complements existing genomic risk tools.”
